Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lipopolysaccharide (LPS) was found to induce inflammatory responses in the airways and exerted as a potent stimulus for PG synthesis. This study was to determine the mechanisms of LPS-enhanced cyclooxygenase (COX)-2 expression associated with
PGE
(2) synthesis in tracheal smooth muscle cells (TSMCs). LPS markedly increased the expression of COX-2 and release of
PGE
(2) in a time- and concentration-dependent manner, whereas COX-1 remained unaltered. Both the expression of COX-2 and the generation of
PGE
(2) in response to LPS were attenuated by a tyrosine kinase inhibitor genistein, a phosphatidylcholine-phospholipase C inhibitor D609, a phosphatidylinositol-phospholipase C inhibitor U73122, protein kinase C inhibitors, GF109203X and staurosporine, removal of Ca(2+) by addition of BAPTA/AM plus EGTA, and phosphatidylinositol 3-kinase (PI3-K) inhibitors, LY294002 and wortmannin. Furthermore, LPS-induced NF-kappaB activation correlated with the degradation of IkappaB-alpha, COX-2 expression, and
PGE
(2) synthesis, was inhibited by transfection with dominant negative mutants of NIK and IKK-alpha, but not by IKK-beta. LPS-induced COX-2 expression and
PGE
(2) synthesis were completely inhibited by PD98059 (an inhibitor of MEK1/2) and SB203580 (an inhibitor of p38
MAPK
inhibitor), but these two inhibitors had no effect on LPS-induced NF-kappaB activation, indicating that NF-kappaB is activated by LPS independently of activation of p42/p44
MAPK
and p38
MAPK
pathways in TSMCs. Taken together, these findings suggest that the increased expression of COX-2 correlates with the release of
PGE
(2) from LPS-challenged TSMCs, at least in part, independently mediated through MAPKs and NF-kappaB signalling pathways. LPS-mediated responses were modulated by PLC, Ca(2+), PKC, tyrosine kinase, and PI3-K in these cells.
...
PMID:Induction of cyclooxygenase-2 by lipopolysaccharide in canine tracheal smooth muscle cells: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-kappaB pathways. 1263 13
Increased levels of isoprostanes have been detected in human atherosclerotic lesions. To examine a possible role for 8-iso-prostaglandin E(2) (8-iso-
PGE
(2)) in atherogenesis, we tested the effect of 8-iso-
PGE
(2) on adhesion of leukocytes to human umbilical vein endothelial cells (EC). We demonstrate that 8-iso-
PGE
(2) stimulates EC to bind monocytes, but not neutrophils. This effect was inhibited by the thromboxane A(2) receptor antagonist SQ29548. Moreover, 8-iso-
PGE
(2) increased levels of cyclic AMP in EC, and monocyte adhesion induced by 8-iso-
PGE
(2) was blocked by a protein kinase A inhibitor, H89. In addition, 8-iso-
PGE
(2 )induced phosphorylation of p38 and
extracellular signal-regulated kinase
(
ERK
) 1/2 mitogen-activated protein (MAP) kinase and stimulated expression of EGR-1. A specific inhibitor of p38 MAP kinase (SB203580) abrogated monocyte binding, whereas an inhibitor of the
ERK
pathway (PD98059) did not block monocyte adhesion induced by 8-iso-
PGE
(2). Activation of nuclear factor-kappaB (NF-kappaB) and expression of NFkappaB-dependent genes intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin were not induced by 8-iso-
PGE
(2). Taken together, these results demonstrate that 8-iso-
PGE
(2) stimulates EC to specifically bind monocytes, but not neutrophils. This effect is mediated by cyclic AMP/protein kinase A- and p38 MAP kinase-dependent pathways and is independent of the classical inflammatory NFkappaB pathway. Thus, formation of 8-iso-
PGE
(2) may play an important role in chronic inflammatory diseases such as atherosclerosis by increasing adhesion and extravasation of monocytes.
...
PMID:The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. 1271 76
Prostaglandin E(2) (
PGE
(2)) has been implicated as an inducer of angiogenesis in human colon cancer. Here, we demonstrate that
PGE
(2) exposure induces the expression of vascular endothelial growth factor (VEGF) mRNA in HCT116 human colon carcinoma cells that is mediated by the transcriptional activator hypoxia-inducible factor 1 (HIF-1).
PGE
(2) exposure induces the phosphorylation of
extracellular signal-regulated kinase
(
ERK
) and AKT. Pharmacologic inhibition of
ERK
phosphorylation blocks the induction of VEGF mRNA and HIF-1alpha protein expression in response to
PGE
(2) stimulation. Inhibition of C-SRC tyrosine kinase activity also blocks
PGE
(2)-induced HIF-1alpha protein and VEGF mRNA expression without blocking
ERK
phosphorylation. In contrast, phosphorylation of AKT is dependent on
ERK
and C-SRC activity. Thus, the activity of multiple signal transduction pathways is required for the HIF-1-mediated induction of VEGF expression in colon cancer cells exposed to
PGE
(2).
...
PMID:Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. 1272 58
Oncostatin M (OSM), a cytokine of the interleukin-6 family, is expressed in rheumatoid arthritis, multiple sclerosis, multiple myeloma, and other inflammatory and neoplastic conditions. Prostaglandin E(2) (
PGE
(2)), an eicosanoid also associated with inflammation and cancer, has recently been shown to induce OSM expression. We report here that OSM in turn induces
PGE
(2) production by astrocytes and astroglioma cells. More importantly, in combination with the inflammatory mediators IL-1beta, tumor necrosis factor-alpha, and lipopolysaccharide, OSM exhibits a striking synergy, resulting in up to 50-fold higher
PGE
(2) production by astrocytes, astroglioma, and neuroblastoma cell lines. Enhanced
PGE
(2) production by OSM and IL-1beta treatment is explained by their effect on cyclooxygenase-2 (COX-2), an enzyme that catalyzes the committed step in
PGE
(2) synthesis. Of the enzymes involved in
PGE
(2) biosynthesis, only COX-2 mRNA and protein levels are synergistically amplified by OSM and IL-1beta. Nuclear run-on assays demonstrate that OSM and IL-1beta synergistically upregulate transcription of the COX-2 gene, and the mRNA stability assay indicates that COX-2 mRNA is posttranscriptionally stabilized by OSM and IL-1beta. To effect synergy on the
PGE
(2) level, OSM signals in part through its gp130/OSMRbeta receptor, since neutralizing antibodies against gp130 and OSMRbeta, but not LIFRbeta, decrease
PGE
(2) production in response to OSM plus IL-1beta. SB202190 and U0126, inhibitors of p38
MAPK
and
ERK1
/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and
PGE
(2), indicating that these
MAPK
cascades are utilized by both stimuli. This mechanism of
PGE
(2) amplification may be active in brain pathologies where both OSM and IL-1beta are present, such as glioblastomas and multiple sclerosis.
...
PMID:Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide. 1273 Sep 64
Prostaglandins released by injured vascular tissue can modulate smooth muscle cell (SMC) proliferation. The mechanism of action of
PGE
(2) was investigated with porcine coronary artery SMCs obtained by explant culture. DNA and RNA syntheses exhibited a concentration-dependent increase following treatment of quiescent SMCs with
PGE
(2), while PGI(2) had no effect.
PGE
(2) also elevated PCNA expression, bromodeoxyuridine incorporation, and cell number, indicative of a hyperplastic growth response. Furthermore, induction of c-fos expression required activation of both phosphatidylinositol 3-kinase and
mitogen-activated protein kinase
. Contrary to these data, treatment of proliferating cells with
PGE
(2) caused a reduction in DNA synthesis. A role for PKA in either growth stimulation or inhibition was excluded. Interestingly, only quiescent SMCs expressed EP2 receptors, and the selective EP2 receptor agonist butaprost confirmed that this receptor was essential for growth stimulation and possibly inhibition. These data suggest that the growth state-dependent actions of
PGE
(2) on SMC proliferation may be mediated via the EP2 receptor.
...
PMID:PGE(2) stimulates vascular smooth muscle cell proliferation via the EP2 receptor. 1278 5
Signal transduction events in monocyte matrix metalloproteinase (MMP) production have been shown to include a
PGE
(2)-cAMP-dependent step. To determine earlier pathway components, we examined the role of mitogen-activated protein kinases (MAPKs) in the regulation of monocyte MMP-1 and MMP-9, two major MMPs induced by LPS. Stimulation with LPS resulted in the activation of the extracellular signal-regulated kinase 1 and 2 (
ERK1
/2) and mitogen-activated kinase p38. The p38-specific inhibitor SB203580 suppressed p38 activity and MMP-1 mRNA and protein, but increased ERK activity and MMP-9 mRNA and protein. In contrast, the
MAPK
kinase 1/2-specific inhibitor PD98059 inhibited MMP-1 and MMP-9. However, both
MAPK
inhibitors decreased the production of cyclooxygenase-2 and
PGE
(2), but only the inhibition of MMP-1 by SB203580 was reversed by
PGE
(2) or dibutyryl cAMP. Examination of the effect of these
MAPK
inhibitors on the promoters of MMP-1 and MMP-9 revealed that PD98059 inhibited the binding of transcription factors to all of the MMP promoter-specific complementary oligonucleotides tested. However, SB203580 only inhibited the binding of MMP-1-specific CREB and SP 1 oligonucleotides, which was reversed by
PGE
(2). Additionally, SB203580 enhanced transcription factor binding to the oligonucleotides complementary to a NF-kappaB site in the promoter of MMP-9. Thus, LPS induction of MMP-1 production by monocytes is regulated by both
ERK1
/2 and p38, whereas MMP-9 stimulation occurred mainly through the
ERK1
/2 pathway. Moreover, p38 regulates MMP-1 mainly through a
PGE
(2)-dependent pathway, whereas
ERK1
/2-mediated MMP-1 and MMP-9 production involves the activation of additional MMP promoter sites through a
PGE
(2)-independent mechanism.
...
PMID:Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. 1279 56
Based on previous work, we hypothesized that activation of spinal NMDA-receptor initiates activation of the p38 mitogen-activated protein kinase (p38
MAPK
) pathway, leading to spinal release of prostaglandins and hyperalgesia. Accordingly, we examined the effect of intrathecal SD-282, a selective p38
MAPK
inhibitor, on NMDA-induced release of prostaglandin E(2) (
PGE
(2)) and thermal hyperalgesia. Inhibition of spinal p38
MAPK
attenuated both NMDA-evoked release of
PGE
(2) and thermal hyperalgesia. NMDA injection led to increased phospho-p38
MAPK
immunoreactivity in superficial (I-II) dorsal laminae. Co-labeling studies revealed co-localization of activated p38
MAPK
predominantly with microglia but also with a small subpopulation of neurons. Taken together these data suggest a role for p38
MAPK
in NMDA-induced
PGE
(2) release and hyperalgesia, and that microglia is involved in spinal nociceptive processing.
...
PMID:Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. 1282 99
Prostaglandin E(2) (
PGE
(2)) and epinephrine act directly on nociceptors to produce mechanical hyperalgesia through protein kinase A (PKA) alone or through a combination of PKA, protein kinase C epsilon (PKCepsilon), and
extracellular signal-regulated kinase
(
ERK
), respectively. Disruptors of the cytoskeleton (microfilaments, microtubules, and intermediate filaments) markedly attenuated the hyperalgesia in rat paws caused by injection of epinephrine or its downstream mediators. In contrast, the hyperalgesia induced by
PGE
(2) or its mediators was not affected by any of the cytoskeletal disruptors. These effects were mimicked in vitro, as measured by enhancement of the tetrodotoxin-resistant sodium current. When
PGE
(2) hyperalgesia was shifted to dependence on PKCepsilon and
ERK
as well as PKA, as when the tissue is "primed" by prior treatment with carrageenan, it too became dependent on an intact cytoskeleton. Thus, inflammatory mediator-induced mechanical hyperalgesia was differentially dependent on the cytoskeleton such that cytoskeletal dependence correlated with mediation by PKCepsilon and
ERK
.
...
PMID:Role of the sensory neuron cytoskeleton in second messenger signaling for inflammatory pain. 1292 70
In this study, we investigated the effect of prostaglandin E(2) (
PGE
(2)) on
MAPK
ERK1
/2 protein phosphorylation and on proliferation of epithelial cells of the human endometrium. Treatment of proliferative phase endometrium with
PGE
(2) induced rapid phosphorylation of
ERK1
/2 proteins in glandular epithelial and endothelial cells. Treatment of human endometrial tissue with
PGE
(2) for 24 h resulted in increased incorporation of 5-bromo-2'-deoxyuridine (a marker of cellular proliferation) in glandular epithelial cells. To investigate further the effect of
PGE
(2) on proliferation of epithelial cells, we used an endometrial epithelial cell line (HES). HES cells express functional EP4 (with absence of expression of EP1, EP2, and EP3) receptors and stimulate cAMP release and rapid phosphorylation of
ERK1
/2 proteins in response to
PGE
(2) or forskolin. Treatment of HES cells with
PGE
(2) or forskolin alone resulted in a significant increase in HES cell proliferation compared with control untreated cells (P < 0.05). Cotreatment of the cells with
PGE
(2) or forskolin and PD98059 abolished the increase in cellular proliferation. These data demonstrate
ERK1
/2 phosphorylation in response to
PGE
(2) in the human endometrium and suggest that
PGE
(2) via EP4 receptor may induce glandular epithelial cell proliferation in
ERK1
/2- dependent manner during the proliferative phase of the menstrual cycle.
...
PMID:Prostaglandin E2 induces proliferation of glandular epithelial cells of the human endometrium via extracellular regulated kinase 1/2-mediated pathway. 1297 Mar 27
Phospholipase C induced phosphoinositide (PI) turnover, intracellular Ca(2+) ([Ca(2+)](i)) mobilization and mitogen-activated protein (MAP) kinase activation by FP-class prostaglandin analogs was studied in normal human ciliary muscle (h-CM) cells. Agonist potencies obtained in the PI turnover assays were: travoprost acid ((+)-fluprostenol; EC(50) = 2.6 +/- 0.8 nM) > bimatoprost acid (EC(50) = 3.6 +/- 1.2 nM) > (+/-)-fluprostenol (EC(50) = 4.3 +/- 1.3 nM) >> prostaglandin F(2 alpha) (PGF(2 alpha)) (EC(50) = 134 +/- 17 nM) > latanoprost acid (EC(50) = 198 +/- 83 nM) > S-1033 (EC(50) = 2930 +/- 1420 nM) > unoprostone (EC(50) = 5590 +/- 1490 nM) > bimatoprost (EC(50) = 9600 +/- 1100 nM). Agonist potencies in h-CM cells correlated well with those previously obtained for the cloned human ciliary body-derived FP receptor (r = 0.96, p< 0.001) and that present on h-TM cells (r = 0.94, p< 0.0001). Travoprost acid, PGF(2 alpha) and unoprostone also stimulated [Ca(2+)](i) mobilization in h-CM cells with travoprost acid being the most potent agonist.
MAP kinase
activity was stimulated in the h-CM cells with the following rank order of activity (at 100 nM): travoprost acid > PGF(2 alpha) > latanoprost acid > PGD(2) > bimatoprost > latanoprost = bimatoprost acid = fluprostenol >
PGE
(2) = S-1033 > unoprostone > PGI(2). The PI turnover, [Ca(2+)](i) mobilization and
MAP kinase
activation induced by several of these agonists was blocked by the FP receptor antagonist, AL-8810 (11 beta-fluoro-15-epiindanyl PGF(2 alpha)) (e.g. K(i) = 5.7 microM versus PI turnover). These studies have characterized the biochemical and pharmacological properties of the native FP prostaglandin receptor present on h-CM cells using three signal transduction mechanism assays and a broad panel of FP-class agonist analogs (including free acids of bimatoprost, travoprost and latanoprost) and the FP receptor antagonist, AL-8810.
...
PMID:Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. 1458 36
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>